Home Cart Sign in  
Chemical Structure| 928037-13-2 Chemical Structure| 928037-13-2

Structure of Golvatinib
CAS No.: 928037-13-2

Chemical Structure| 928037-13-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Golvatinib is a dual c-Met and VEGFR-2 inhibitor with IC50 of 14 nM and 16 nM.

Synonyms: E-7050

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Golvatinib

CAS No. :928037-13-2
Formula : C33H37F2N7O4
M.W : 633.69
SMILES Code : O=C(C1(C(NC2=CC=C(F)C=C2)=O)CC1)NC3=CC=C(OC4=CC(NC(N5CCC(N6CCN(C)CC6)CC5)=O)=NC=C4)C=C3F
Synonyms :
E-7050
MDL No. :MFCD22124462
InChI Key :UQRCJCNVNUFYDX-UHFFFAOYSA-N
Pubchem ID :16118392

Safety of Golvatinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Golvatinib

RTK

Isoform Comparison

Biological Activity

Target
  • VEGFR2

    VEGFR2, IC50:16 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
A549 cells 8.14 ± 0.45 µM 72 h To evaluate the antitumor activity of Golvatinib against A549 cells, the results showed an IC50 value of 8.14 ± 0.45 µM PMC6983042
HeLa cells 15.17 ± 0.17 µM 72 h To evaluate the antitumor activity of Golvatinib against HeLa cells, the results showed an IC50 value of 15.17 ± 0.17 µM PMC6983042
MCF-7 cells 16.91 ± 0.29 µM 72 h To evaluate the antitumor activity of Golvatinib against MCF-7 cells, the results showed an IC50 value of 16.91 ± 0.29 µM PMC6983042
HUVECs 30 nM 3 days To investigate the effect of Golvatinib on HGF-induced resistance to Lenvatinib, results showed that the combination of Golvatinib with Lenvatinib significantly inhibited the proliferation of HUVECs PMC4317894

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice K1 ⁄Ang2 and AN3CA xenograft models Oral 100 mg/kg Once daily until the end of the experiment Golvatinib combined with lenvatinib showed antitumor effects in both K1 ?Ang2 and AN3CA models, significantly reducing blood perfusion and increasing apoptosis. PMC4399030
Nude mice K1/Ang2 and AN3CA xenograft models Oral 100 mg/kg Once daily until the end of the experiment To evaluate the effect of Golvatinib in combination with Lenvatinib on tumor growth. Results showed that the combination of Golvatinib and Lenvatinib significantly inhibited tumor growth, leading to severe perfusion disorder and massive apoptosis. PMC4399030
Nude mice Human tumor xenograft models Oral 100 mg/kg Once daily for 8-21 days To investigate the antitumor effect of Golvatinib in combination with Lenvatinib on HGF-overexpressing tumors, results showed that the combination therapy significantly inhibited tumor growth PMC4317894

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.58mL

0.32mL

0.16mL

7.89mL

1.58mL

0.79mL

15.78mL

3.16mL

1.58mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories